TY  - JOUR
AU  - Horak, Peter
AU  - Klink, Barbara
AU  - Heining, Christoph
AU  - Gröschel, Stefan
AU  - Hutter, Barbara
AU  - Fröhlich, Martina Antonia
AU  - Uhrig, Sebastian
AU  - Hübschmann, Daniel
AU  - Schlesner, Matthias
AU  - Eils, Roland
AU  - Richter, Daniela
AU  - Pfütze, Katrin
AU  - Geörg, Christina
AU  - Meißburger, Bettina
AU  - Wolf, Stephan
AU  - Schulz, Angela
AU  - Penzel, Roland
AU  - Herpel, Esther
AU  - Kirchner, Martina
AU  - Lier, Amelie
AU  - Endris, Volker
AU  - Singer, Stephan
AU  - Schirmacher, Peter
AU  - Weichert, Wilko
AU  - Stenzinger, Albrecht
AU  - Schlenk, Richard
AU  - Schröck, Evelin
AU  - Brors, Benedikt
AU  - von Kalle, Christof
AU  - Glimm, Hanno
AU  - Fröhling, Stefan
TI  - Precision oncology based on omics data: The NCT Heidelberg experience.
JO  - International journal of cancer
VL  - 141
IS  - 5
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2017-01421
SP  - 877 - 886
PY  - 2017
AB  - Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments.
LB  - PUB:(DE-HGF)16
C6  - pmid:28597939
DO  - DOI:10.1002/ijc.30828
UR  - https://inrepo02.dkfz.de/record/125283
ER  -